Evidence map›Paper›PMID 28594860›Full record

SynthesisPloS one2017

Effect of probiotic Lactobacillus on lipid profile: A systematic review and meta-analysis of randomized, controlled trials.

Yucheng Wu, Qingqing Zhang, Yin Ren, Zhongbao Ruan

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 81 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05194033 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 1)

TypeinterventionalSponsorPeking UniversityRan2022 to 2022Enrolled31ConditionsSARS-CoV-2ArmsProbiotics daily, Placebo daily
NCT05195047 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 2)

TypeinterventionalSponsorPeking UniversityRan2022 to 2022Enrolled44ConditionsSARS-CoV-2Arms1 week placebo(Week 1), 1 week of probiotics(Week 1), 1 week placebo(Week 2), 1 week of probiotics(Week 2), 1 week placebo(Week 3)
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. The Role ofInternational journal of molecular sciences · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Effect ofNutrients · 2026
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Safety and Effects ofNutrients · 2023
    Trial
  17. A Combination ofNutrients · 2021
    Trial
  18. Trial
  19. Gut microbial alterations and functional shifts in patients with hypertriglyceridemia: insights from a northwestern Chinese metagenomic study.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yucheng WuDepartment of Cardiology, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Qingqing ZhangDepartment of Endocrinology, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Yin RenDepartment of Cardiology, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Zhongbao RuanDepartment of Cardiology, Taizhou People's Hospital, Taizhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the efficacy of probiotic Lactobacillus on serum lipids using a meta-analysis of randomized, controlled trials.

methodsFifteen studies containing 15 trials, with 976 subjects were included. The pooled WMD was calculated by random effects model.

resultsProbiotic Lactobacillus consumption significantly reduced TC by 0.26mmol/l (95% CI, -0.40 to -0.12) and LDL-C by 0.23mmol/l (95% CI, -0.36 to -0.10). Subgroup analysis of trials found significantly reduction of TC using L. plantarum and reduction of LDL-C using L. plantarum or L. reuteri. No significant effects were found on TG and HDL-C levels after supplementation with probiotic Lactobacillus. While, subgroup analysis found significantly beneficial effects on TG and HDL-C by consuming synbiotic food, containing L. sporogenes and inulin.

conclusionConsuming probiotic Lactobacillus, especially L. reuteri and L. plantarm, could reduce TC and LDL-C significantly. The study also suggested significantly beneficial effects on TG and HDL-C by consuming synbiotic food, containing L. sporogenes and inulin.

Indexed as

Cholesterol, HDLCholesterol, LDLLactobacillusLipid MetabolismProbioticsRandomized Controlled Trials as TopicTriglyceridesCholesterol, HDLCholesterol, LDLTriglycerides

Identifiers

PMID28594860
PMCPMC5464580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.